Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network-Reference-Cited by-同舟云学术

Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network

Published:2024-05-03 Issue:5 Volume:24 Page:399-409
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Spini Andrea¹^ORCID,Pellegrini Giorgia¹,Ingrasciotta Ylenia¹^ORCID,L’Abbate Luca²,Bellitto Chiara¹,Carollo Massimo¹^ORCID,Leoni Olivia³,Zanforlini Martina⁴,Ancona Domenica⁵,Stella Paolo⁵,Cavazzana Anna⁶,Scapin Angela⁶,Lopes Sara⁷,Belleudi Valeria⁷^ORCID,Ledda Stefano⁸,Carta Paolo⁸,Rossi Paola⁹,Ejlli Lucian⁹,Sapigni Ester¹⁰,Puccini Aurora¹⁰,Spila Alegiani Stefania¹¹,Massari Marco¹¹,Guarneri Claudio¹²,Gisondi Paolo¹³^ORCID,Trifirò Gianluca¹^ORCID

Affiliation:

1. Department of Diagnostics and Public Health, University of Verona, Verona, Italy

2. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy

3. Lombardy Regional Centre of Pharmacovigilance and Regional Epidemiologic Observatory, Milan, Italy

4. Azienda Regionale per l’Innovazione e gli Acquisti, S.p.A, Milan, Italy

5. Centro Regionale di Farmacovigilanza Regione Puglia, Bari, Italy

6. Azienda Zero, Regione Veneto, Italy

7. Department of Epidemiology, Lazio Regional Health Service, Rome, Italy

8. Regione Autonoma della Sardegna, Cagliari, Italy

9. Friuli-Venezia Giulia Regional Center of Pharmacovigilance, Trieste, Italy

10. Emilia-Romagna Regional Center of Pharmacovigilance, Bologna, Italy

11. Pharmacoepidemiology and Pharmacovigilance Unit, National Centre for Drug Research and Evaluation, Italian National Institute of Health (ISS), Rome, Italy

12. University of Messina, AOU “G.Martino”, Messina, Italy

13. Department of Medicine, University of Verona, Verona, Italy

Funder

Italian Medicines Agency

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2024.2357381

Reference36 articles.

1. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease

2. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders

3. What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?

4. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

5. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation